Readers invited to submit opinions

Adaptive clinical trials require dynamic thinking in many areas, among them cost estimating. As ClearTrial CEO Mike Soenen persuasively explains in our first Op-ed Corner article, applying old cost estimating techniques used in traditional clinical trials will not do for dynamic adaptive trials.

Soenen makes his case well in few words, and I invite all readers who similarly wish to express a biotech IT-related opinion (no announcements or product pitches, please) to submit them to me at [email protected] - George

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.